These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35095916)

  • 1. Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
    Moreira TG; Matos KTF; De Paula GS; Santana TMM; Da Mata RG; Pansera FC; Cortina AS; Spinola MG; Baecher-Allan CM; Keppeke GD; Jacob J; Palejwala V; Chen K; Izzy S; Healey BC; Rezende RM; Dedivitis RA; Shailubhai K; Weiner HL
    Front Immunol; 2021; 12():815812. PubMed ID: 35095916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
    Moreira TG; Matos KTF; De Paula GS; Santana TMM; Da Mata RG; Pansera FC; Cortina AS; Spinola MG; Baecher-Allan CM; Keppeke GD; Jacob J; Palejwala V; Chen K; Izzy S; Healey BC; Rezende RM; Dedivitis RA; Shailubhai K; Weiner HL
    Front Immunol; 2021; 12():709861. PubMed ID: 34475873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal administration of anti-CD3 mAb (Foralumab) downregulates
    G Moreira T; Gauthier CD; Murphy L; Lanser TB; Paul A; Matos KTF; Mangani D; Izzy S; Rezende RM; Healy BC; Baecher-Allan CM; Chitnis T; Kuchroo V; Weiner HL
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2220272120. PubMed ID: 36881624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection Effect of Anti-CD3 Monoclonal Antibody on Primo Vessel in Lymph Vessel of Rabbit with Lipopolysaccharide-Induced Inflammation.
    Choi SH; Choi JG; Lee SS
    J Acupunct Meridian Stud; 2022 Feb; 15(1):37-42. PubMed ID: 35770572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.
    Santos IKFM; Costa CHN
    Front Immunol; 2020; 11():615628. PubMed ID: 33224154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response Up to 10 Months.
    Kaaijk P; Olivo Pimentel V; Emmelot ME; Poelen MCM; Cevirgel A; Schepp RM; den Hartog G; Reukers DFM; Beckers L; van Beek J; van Els CACM; Meijer A; Rots NY; de Wit J
    Front Immunol; 2022; 13():893720. PubMed ID: 35572580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19.
    Adhikari B; Bednash JS; Horowitz JC; Rubinstein MP; Vlasova AN
    Front Immunol; 2024; 15():1384209. PubMed ID: 38482012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity.
    Kang CK; Kim M; Hong J; Kim G; Lee S; Chang E; Choe PG; Kim NJ; Kim IS; Seo JY; Song D; Lee DS; Shin HM; Kim YW; Lee CH; Park WB; Kim HR; Oh MD
    Front Immunol; 2022; 13():929770. PubMed ID: 35686133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice.
    Ogura M; Deng S; Preston-Hurlburt P; Ogura H; Shailubhai K; Kuhn C; Weiner HL; Herold KC
    Clin Immunol; 2017 Oct; 183():240-246. PubMed ID: 28739191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
    Ilan Y; Shailubhai K; Sanyal A
    Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID.
    Goh D; Lim JCT; Fernaíndez SB; Joseph CR; Edwards SG; Neo ZW; Lee JN; Caballero SG; Lau MC; Yeong JPS
    Front Immunol; 2022; 13():1036894. PubMed ID: 36275692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients.
    Giron LB; Dweep H; Yin X; Wang H; Damra M; Goldman AR; Gorman N; Palmer CS; Tang HY; Shaikh MW; Forsyth CB; Balk RA; Zilberstein NF; Liu Q; Kossenkov A; Keshavarzian A; Landay A; Abdel-Mohsen M
    Front Immunol; 2021; 12():779064. PubMed ID: 34671365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia.
    Jeon K; Kim Y; Kang SK; Park U; Kim J; Park N; Koh J; Shim MS; Kim M; Rhee YJ; Jeong H; Lee S; Park D; Lim J; Kim H; Ha NY; Jo HY; Kim SC; Lee JH; Shon J; Kim H; Jeon YK; Choi YS; Kim HY; Lee WW; Choi M; Park HY; Park WY; Kim YS; Cho NH
    Front Immunol; 2023; 14():1175767. PubMed ID: 36969212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: The effects of COVID-19 on the placenta during pregnancy.
    Rad HS; Röhl J; Stylianou N; Allenby MC; Bazaz SR; Warkiani ME; Guimaraes FSF; Clifton VL; Kulasinghe A
    Front Immunol; 2022; 13():998406. PubMed ID: 36159853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis.
    Samans B; Rosselló Chornet M; Rosselló Chornet A; Jung J; Schildknecht K; Lozza L; Alos Zaragoza L; Hernández Laforet J; Babel N; Olek S
    Front Immunol; 2024; 15():1451571. PubMed ID: 38994367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
    Khatri I; Staal FJT; van Dongen JJM
    Front Immunol; 2021; 12():659375. PubMed ID: 33936092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy.
    Hasankhani A; Bahrami A; Tavakoli-Far B; Iranshahi S; Ghaemi F; Akbarizadeh MR; Amin AH; Abedi Kiasari B; Mohammadzadeh Shabestari A
    Front Immunol; 2024; 15():1422261. PubMed ID: 38779659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: A potential bioelectromagnetic method to slow down the progression and prevent the development of ultimate pulmonary fibrosis by COVID-19.
    Masaud SM; Szasz O; Szasz AM; Ejaz H; Anwar RA; Szasz A
    Front Immunol; 2022; 13():1094086. PubMed ID: 36483547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk.
    Tsilika M; Taks E; Dolianitis K; Kotsaki A; Leventogiannis K; Damoulari C; Kostoula M; Paneta M; Adamis G; Papanikolaou I; Stamatelopoulos K; Bolanou A; Katsaros K; Delavinia C; Perdios I; Pandi A; Tsiakos K; Proios N; Kalogianni E; Delis I; Skliros E; Akinosoglou K; Perdikouli A; Poulakou G; Milionis H; Athanassopoulou E; Kalpaki E; Efstratiou L; Perraki V; Papadopoulos A; Netea MG; Giamarellos-Bourboulis EJ
    Front Immunol; 2022; 13():1018384. PubMed ID: 36119100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.